Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript
Alamar Biosciences (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with gross margin at 61.5%. Net loss was $13.3M. Full-year revenue guidance raised to $121M-$123M. Company finalized large-scale studies with UK Biobank and GSK, focusing on neurodegenerative and inflammatory diseases. Cash position at $231.5M supports expansion plans. President Todd White to retire by year-end.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise are likely to drive short‑term price appreciation, while long‑term investors will watch cash runway and customer concentration.
Market read
First‑time earnings disclosure with material growth metrics; actionable for traders seeking exposure to biotech services.
What to watch
High SG&A spend and reliance on a few biopharma customers could increase concentration risk.
Background
Alamar Biosciences reported Q3 2026 results, highlighting rapid revenue growth, record gross margin, and a raised full‑year revenue outlook.
Ticker impact
Q3 2026 earnings released with 68% revenue growth, record gross margin and raised full-year guidance to $121‑$123M.
likely upward pressure as investors price in higher revenue growth and improved margins.
Strong top‑line growth, margin expansion, and cash position reduce near‑term risk and support a higher valuation.
Market effects
Boosts outlook for the proteomics and biotech services sector.
Highlights growth in US and international markets for high‑throughput protein platforms.
Adds to broader biotech earnings momentum but limited to niche market.
Counterpoint
Margin expansion may be temporary if instrument costs rise; guidance could be revised down if sales cycles slow.
Key entities
- companyAlamar Biosciences
US‑listed proteomics platform provider (ticker ALMR).


